Sign Up Today and Learn More About Better Therapeutics Stock

Invest in or calculate the value of your shares in Better Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Better Therapeutics Stock

Better develops prescription software for treating cardiometabolic diseases.

About Better Therapeutics Stock




San Francisco, CA, US

Better Therapeutics discovers, develops and commercializes prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases. We use clinically-validated, FDA-regulated software to change the behaviors that cause these diseases thereby improving quality of life, reducing the need for medications, and lowering costs. Our products deliver digital behavioral therapy that integrates neuroscience, lifestyle medicine, and explainable AI into a physician-prescribed mobile medical app, and uses patient-generated data to inform clinical decision-making and improve treatment outcomes. Our current product pipeline includes therapeutic candidates for the treatment of type 2 diabetes, hypertension, and dyslipidemia. Our founding team has started, led and exited multiple technology companies that have transformed industries and generated billions of dollars in enterprise value. The 17th Surgeon General of the US, Dr. Richard Carmona, serves as an independent board director. We were founded in 2015 and are headquartered in San Francisco, CA.

Better Therapeutics Press Mentions

Stay in the know about the latest news on Better Therapeutics

Better Therapeutics Management

Leadership team at Better Therapeutics

Operations Lead

Lauren Burns

Care Ambassador

Kate Edwards, FNPC, MSN, RN

Locked Features

Join now and verify your accreditation status to gain access to:

  • Better Therapeutics current valuation
  • Better Therapeutics stock price
  • Available deals in Better Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Better Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Better Therapeutics through EquityZen funds. These investments are made available by existing Better Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Better Therapeutics stock?

Shareholders can sell their Better Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."